Linnea Cipriano is a partner in Goodwin's Intellectual Property Litigation practice, specializing in patent litigation in federal courts and the U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB).
Linnea’s federal court practice focuses on clients in the life science industry, representing both plaintiffs and defendants in high stakes patent litigations. Linnea’s experience includes technologies across the life science industry, including biotechnology, cell and gene therapies, small and large molecule pharmaceuticals, nutritional supplements, chemical manufacturing, medical devices, and drug delivery technologies.
Linnea also co-leads Goodwin’s post-grant proceedings practice and was shortlisted for LMG Life Sciences Post Grant Proceedings Attorney of the Year in 2024. At the PTAB, she has successfully represented petitioners and patent owners in a diverse spectrum of industries, encompassing pharmaceuticals, cell therapies, electronic devices, manufacturing methods, and medical devices.
Linnea blends her scientific background with her legal expertise to serve her clients with unparalleled dedication and insight.
Representative Matters
Professional Experience
Prior to joining Goodwin, Linnea was an associate in the New York office of Kenyon & Kenyon. She also worked as a legal intern at Cleveland Clinic Innovations and as a research technologist at the Cleveland Clinic Foundation.
Linnea served on the Board of NYIPLA 2022-2024 and currently serves as co-chair of the NYIPLA Women in IP Law Committee. She is also a member of the PTAB Bar Association and the ChIPs Network.
Credentials
Education
JD2010
Case Western Reserve University
MSPharmacology2007
Case Western Reserve University
BSBiochemistry2004
Catholic University of America
Admissions
Bars
- New York
- U.S. Patent and Trademark Office (USPTO)
Courts
- U.S. District Court for the Southern District of New York
- U.S. Court of Appeals for the Federal Circuit
Recognition & Awards
- LMG Life Sciences Post Grant Proceedings Attorney of the Year Shortlist (2024)
- IAM Patent 1000 (2022, 2023, 2024)
- Super Lawyers (2015-2021)
- The Legal 500 (2021)
Publications
- Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S. 2023-2024 ed.,” published by Thomson Reuters, January 2024
- Co-Author, “Key PTAB Priorities And changes Under Vidal,” Law 360, June 2023
- Co-Author, “3 Best Practices For Patent Claims Against Secret Methods,” Law360, August 12, 2019
- Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed.,” published by Thomson Reuters, November 2019
Linnea is the managing editor of the Goodwin PTAB Trial Tracker periodic newsletter.